Cargando…

High mobility group protein B1 is a predictor of poor survival in ovarian cancer

High-mobility group protein B1 (HMGB1) has been implicated in numerous tumour types where expression regulates tumour cell growth and survival. We hypothesised that high HMGB1 expression in ovarian tumours would predict poor patient survival. Using tissue microarrays of primary ovarian cancers combi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Machado, Lee R., Moseley, Paul M., Moss, Robert, Deen, Suha, Nolan, Christopher, Spendlove, Ian, Ramage, Judith M., Chan, Stephen YT., Durrant, Lindy G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731868/ https://www.ncbi.nlm.nih.gov/pubmed/29254158 http://dx.doi.org/10.18632/oncotarget.20538

Ejemplares similares

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer
por: Popple, A, et al.
Publicado: (2012)

Therapeutic Targeting of Lewis(y) and Lewis(b) with a Novel Monoclonal Antibody 692/29
por: Noble, Philip, et al.
Publicado: (2013)

Connexin 43 is an independent predictor of patient outcome in breast cancer patients
por: Chasampalioti, Maria, et al.
Publicado: (2018)

High expression of Lewis(y/b )antigens is associated with decreased survival in lymph node negative breast carcinomas
por: Madjd, Zahra, et al.
Publicado: (2005)

Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: A tissue microarray study of 460 patients
por: Watson, Nicholas FS, et al.
Publicado: (2005)

High BMP7 expression is associated with poor prognosis in ovarian cancer
por: Vasan, Richa, et al.
Publicado: (2023)

Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy
por: Shehata, M, et al.
Publicado: (2009)

SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade
por: Xue, Wei, et al.
Publicado: (2016)

CD55 is over-expressed in the tumour environment
por: Li, L, et al.
Publicado: (2001)

Expression of Syk and MAP4 proteins in ovarian cancer
por: Zhang, Siwei, et al.
Publicado: (2019)

Most functional outcomes are similar for men and women after hip fracture: a secondary analysis of the enhancing mobility after hip fracture trial
por: Woodward, Lynda M, et al.
Publicado: (2014)

Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer
por: Coveney, Clare, et al.
Publicado: (2015)

Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer
por: Storr, Sarah J, et al.
Publicado: (2012)

Higher thymocyte selection-associated high mobility group box (TOX) expression predicts poor prognosis in patients with ovarian cancer
por: Li, Sai, et al.
Publicado: (2022)

Calpain system protein expression and activity in ovarian cancer
por: Zhang, Siwei, et al.
Publicado: (2018)

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer
por: Abdel-Fatah, T M A, et al.
Publicado: (2014)

Stromal fibroblasts support dendritic cells to maintain IL-23/Th17 responses after exposure to ionizing radiation
por: Malecka, Anna, et al.
Publicado: (2016)

1013. Outpatient parenteral antimicrobial therapy (OPAT)-related peripheral eosinophilia as a predictor of hypersensitivity reactions.
por: Khalaf, Suha Abu, et al.
Publicado: (2022)

Total Colonic Expulsion with Part of Small Bowel per Vaginum due to Low-Flow Phenomenon and NOMI: A Case Report
por: Deen, Suha, et al.
Publicado: (2011)

Identification of High-Mobility Group Box 1 (HMGB1) Expression as a Potential Predictor of Rejection and Poor Prognosis After Liver Transplantation
por: Ye, Zhou, et al.
Publicado: (2021)

Vaccine Can Induce CD4-Mediated Responses to Homocitrullinated Peptides via Multiple HLA-Types and Confer Anti-Tumor Immunity
por: Cook, Katherine, et al.
Publicado: (2022)

SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors
por: Xue, Wei, et al.
Publicado: (2016)

Dopamine and cAMP‐regulated phosphoprotein 32kDa (DARPP‐32), protein phosphatase‐1 and cyclin‐dependent kinase 5 expression in ovarian cancer
por: Martin, Stewart G., et al.
Publicado: (2020)

Combination Treatment with an Antibody–Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer
por: Wan, Y. Louise, et al.
Publicado: (2019)

Correction to: Combination Treatment with an Antibody–Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer
por: Wan, Y. Louise, et al.
Publicado: (2019)

Poor ovarian reserve
por: Jirge, Padma Rekha
Publicado: (2016)

High mobility group box 2 modulates the progression of osteosarcoma and is related with poor prognosis
por: Yang, Shicong, et al.
Publicado: (2020)

Pivotal role of High-Mobility Group Box 2 in ovarian folliculogenesis and fertility
por: Shirouzu, Shinichiro, et al.
Publicado: (2022)

Comparison of mild ovarian stimulation with conventional ovarian stimulation in poor responders
por: Yoo, Ji Hee, et al.
Publicado: (2011)

High mobility group box 1 levels as potential predictors of asthma severity
por: Xu, Shuanglan, et al.
Publicado: (2023)

Exercise to Reduce Mobility Disability and Prevent Falls After Fall-Related Leg or Pelvic Fracture: RESTORE Randomized Controlled Trial
por: Sherrington, Catherine, et al.
Publicado: (2020)

Cancer cell associated glycans as targets for immunotherapy
por: Vankemmelbeke, Mireille, et al.
Publicado: (2015)

A validation study of a smartphone application for functional mobility assessment of the elderly
por: Chan, Matthew H.M., et al.
Publicado: (2016)

High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer
por: Barreiro-Alonso, Aida, et al.
Publicado: (2016)

Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma
por: Yang, Guo-Fen, et al.
Publicado: (2010)

Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer
por: Matsubara, Yuko, et al.
Publicado: (2019)

Activated tissue resident memory T-cells (CD8+CD103+CD39+) uniquely predict survival in left sided “immune-hot” colorectal cancers
por: Talhouni, Shahd, et al.
Publicado: (2023)

Correction: Pivotal role of High-Mobility Group Box 2 in ovarian folliculogenesis and fertility
por: Shirouzu, Shinichiro, et al.
Publicado: (2023)

Current Strategies to Enhance Anti-Tumour Immunity
por: Cook, Katherine W., et al.
Publicado: (2018)

Luteal phase ovarian stimulation for poor ovarian responders
por: Zhang, Wei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s78ktqfqa3tlhg9mobek14ibns